MAGELLAN LONGEVITY
Home › Research › Study library › Does carnosine supplementation improve cardiometabolic health and…
Study summary · Metabolic health, glucose & body composition

Does carnosine supplementation improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes?

BMJ Open · 2017 · PMID 28864708 · DOI 10.1136/bmjopen-2017-017691

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

This study protocol outlines a trial to investigate if carnosine supplementation improves cardiometabolic health and cognitive function in individuals with pre-diabetes and type 2 diabetes.

The question

Does carnosine supplementation improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes?

What they tested

The study aims to investigate if carnosine supplementation improves cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes.

How they did it

This will be a parallel design randomized controlled trial. Fifty participants aged 18-70 with pre-diabetes or T2DM (HbA1c < 8%) will be randomly assigned to either an intervention group receiving 2g of carnosine daily or a control group receiving an identical placebo for 14 weeks. Baseline and post-intervention measurements will include anthropometrics, oral glucose tolerance, cardiovascular parameters, cognitive function, physical activity, heart rate variability, liver fibroscan, and questionnaires on dietary habits, sleep, depression, and quality of life. Changes in these parameters will be compared between groups.

What they found

This is a study protocol, and no results are available yet.

What it means

This is a study protocol, and no conclusions can be drawn yet.

Limitations

This is a study protocol, and limitations of the study design are not discussed in the abstract.

“carnosine preserves insulin sensitivity and secretion in overweight and obese individuals”— from the published abstract, BMJ Open 2017

The paper at a glance

Magellan’s evidence labelanti-glycation dipeptide antioxidant (our label for this citation — see PubMed for the paper’s own title and authors)
JournalBMJ Open
Year2017
PMID28864708 ↗
DOI10.1136/bmjopen-2017-017691 ↗
TopicMetabolic health, glucose & body composition

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Carnosine

Meta-analyses of randomized trials indicate that carnosine or beta-alanine supplementation modestly improves glycemic control, lowering fasting glucose and HbA1c, in people with prediabetes or type 2 diabetes, and pooled trials of histidine-containing dipeptides also report reduced waist circumference and a small…

Carnosine

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide, composed of the amino acids…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Heart rate variabilityExercise trainingHbA1cSleep

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does carnosine supplementation improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? [Plain-English summary of BMJ Open 2017, PMID 28864708, DOI 10.1136/bmjopen-2017-017691]. Magellan Longevity. https://magellanlongevity.com/study/s139.html
BibTeX
@misc{magellan_s139, title = {Does carnosine supplementation improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s139.html}}, note = {Plain-English summary of PubMed PMID 28864708; DOI 10.1136/bmjopen-2017-017691; BMJ Open 2017. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s139.html

Related studies in the Magellan library

All 22 Magellan summaries on metabolic health, glucose & body composition →

How this summary was made. Every section above restates what the published abstract of PMID 28864708 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.